Full-Time
Deepcell
11-50 employees
Biotechnology for cell analysis and sorting
No salary listed
Entry, Junior
Menlo Park, CA, USA
This position is onsite in Menlo Park, CA.
Upload your resume to see how it matches 5 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- Strong analytical and problem-solving skills
- Strong experience with object-oriented design and principles
- Writes high-quality, clean code
- Computer Science degree or equivalent professional experience
- Proficient in C#
- Versed in software engineering best practices (version control, code review process, agile methodology, unit testing, etc.)
- Strongly proficient in object oriented programming (OOP)
- As a C# Software Engineer, you will play a key role in designing and developing the C# desktop application that powers our cutting-edge instruments.
- This software, which integrates hardware, biology, and artificial intelligence, is already in the hands of our customers and actively used by biologists every day to conduct groundbreaking research.
- In this role, your focus will be on ensuring the reliability, performance, and usability of the application, as it is critical to our users' daily work.
- You’ll enhance system capabilities by integrating new hardware and collaborate closely with our scientists to make the instrument smarter and more intuitive.
- Additionally, you will work to continuously refine and improve the architecture of a complex, real-world system, ensuring it remains robust and future-proof.
Deepcell specializes in biotechnology focused on cell analysis and sorting. Its main product, the REM-I platform, utilizes label-free imaging and deep learning to analyze and categorize cells based on their shape and structure. This technology provides a detailed quantitative readout, offering comprehensive data about individual cells. The REM-I platform employs advanced microfluidics to manipulate tiny fluid droplets and artificial intelligence to interpret the imaging data. This allows for in-depth characterization of cells, which is essential for researchers in scientific and medical fields, such as pharmaceutical companies and academic institutions studying diseases. Deepcell's business model likely involves selling or licensing the REM-I platform and offering data analytics services to clients, providing valuable insights from the data collected. The goal of Deepcell is to lead in the field of cell analysis and sorting, making its technology highly sought after by researchers.
Company Size
11-50
Company Stage
Late Stage VC
Total Funding
$178M
Headquarters
Sunnyvale, California
Founded
2015
Simplify's Take
What believers are saying
- Deepcell is raising $80M to expand and accelerate product development.
- Demand for label-free imaging technologies is increasing, aligning with Deepcell's offerings.
- AI in translational research is expanding, enhancing Deepcell's value proposition.
What critics are saying
- Emerging competition from companies like Berkeley Lights could impact Deepcell's market share.
- Rapid technological advancements may require costly updates to Deepcell's REM-I platform.
- Potential ethical concerns and regulatory scrutiny could slow product adoption.
What makes Deepcell unique
- Deepcell's REM-I platform combines label-free imaging with deep learning for cell analysis.
- The company uses advanced microfluidics for precise cell sorting and analysis.
- Deepcell's AI-driven technology provides high-dimensional quantitative readouts of individual cells.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights and Company News
6 month growth
↓ -7%1 year growth
↓ -12%2 year growth
↑ 24%Menlo Park, CA – According to filings with the U.S. Securities and Exchange Commission, Deepcell is raising $80,000,095.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mahdokht Masaeli played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development. About Deepcell
Deepcell, a developer of artificial intelligence-based cell classification and isolation technologies spun out of Stanford University in 2017, said this week it has completed a $20 million Series A financing.
Deepcell, a Mountain View, Calif.-based life science company pioneering AI-powered cell classification and isolation for cell biology and translational research, closed its Series A round of financing with $20m. The round was led by Bow Capital and joined by Andreessen Horowitz, which led its $5m seed round. Other investors include 50Y, DCVC, Stanford University, and […]